Design, Synthesis And Characterization Of Novel Pirtobrutinib Analogues As Anticancer BTK Inhibitors
Adolescência e Saúde · 16.07.2026 · 21 (4s) · 431-439
DOI: 10.67440/ahj.v21i4s.1159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Adolescência e Saúde, online erschienen am 16.07.2026. Verfasst von Dr. Hemant A. Deokule und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bruton tyrosine kinase (BTK) is a validated therapeutic target in B-cell malignancies, and pirtobrutinib is an important non-covalent BTK inhibitor developed to retain activity in settings where resistance to covalent BTK inhibitors may occur. The present manuscript draft describes a rational medicinal-chemistry framework for the design, synthesis and preliminary biological evaluation of novel pirtobrutinib analogues as anticancer BTK inhibitors. A focused analogue library was designed around the pirtobrutinib pharmacophore by retaining the pyrazole-carboxamide hydrogen-bonding region and varying selected aryl, amide, lipophilic and solubilizing substituent zones. Candidate analogues were prioritized using docking-based BTK interaction analysis, physicochemical screening and drug-likeness filters. The proposed synthetic strategy involved modular amide coupling and late-stage substituent diversification, followed by purification and confirmation of chemical identity using FTIR, 1H NMR, 13C NMR, mass spectrometry and elemental analysis. Representative biological assessment included enzyme-based BTK inhibition, cell-viability assays in BTK-dependent B-cell cancer models, selectivity assessment against non-malignant cells, apoptosis markers and preliminary in silico ADMET profiling. The representative dataset suggests that selected analogues with strengthened hinge-region interaction, balanced lipophilicity and improved solubility may demonstrate enhanced BTK inhibition and anticancer response compared with the parent scaffold. The work provides a structured research-paper format for developing pirtobrutinib-inspired analogues and supports further experimental validation through kinase panel screening, resistant-cell models and pharmacokinetic evaluation.
Zitieren
APA
Deokule, D. H. A., Rahane, D. R. D., Kolhe, D. S. S., Kadam, D. N. R., Suryawanshi, M. B., Musale, L. P., Ingole, D. R. D., & Tapare, R. M. (2026). Design, Synthesis And Characterization Of Novel Pirtobrutinib Analogues As Anticancer BTK Inhibitors. Adolescência e Saúde, 21(4s), 431-439. https://doi.org/10.67440/ahj.v21i4s.1159
Vancouver
Deokule DHA, Rahane DRD, Kolhe DSS, Kadam DNR, Suryawanshi MB, Musale LP, et al. Design, Synthesis And Characterization Of Novel Pirtobrutinib Analogues As Anticancer BTK Inhibitors. Adolescência e Saúde. 2026;21(4s):431-439. doi:10.67440/ahj.v21i4s.1159
BibTeX
@article{Deokule2026,
author = {Deokule, Dr. Hemant A. and Rahane, Dr. Rahulkumar D. and Kolhe, Dr. Shilpa S. and Kadam, Dr. Nagnath R. and Suryawanshi, Milind B. and Musale, Laxman Prabhakar and Ingole, Dr. Ramesh D. and Tapare, Ratnadip M.},
title = {Design, Synthesis And Characterization Of Novel Pirtobrutinib Analogues As Anticancer BTK Inhibitors},
journal = {Adolescência e Saúde},
year = {2026},
volume = {21},
number = {4s},
pages = {431--439},
doi = {10.67440/ahj.v21i4s.1159}
}
EUVIMED